Preclinical neuroscience research relies heavily on animal models that often fail to accurately replicate human brain physiology and disease pathology. Traditional 2D cell cultures lack the complexity of the brain's 3D structure and cellular interactions, limiting their predictive power for drug discovery and development. This results in high failure rates in clinical trials and increased costs for pharmaceutical companies.

ZeNEUROID offers advanced 3D and 4D in vitro brain models derived from induced pluripotent stem cells (iPSCs) to enhance preclinical neuroscience research. These bioengineered neurosphere network models mimic the complex structure and function of the human brain, providing a more physiologically relevant platform for studying brain diseases. The platform enables researchers to generate human and mouse brain-relevant data, analyze patient-specific traits, and accelerate the discovery and validation of therapies for neuropsychiatric and neurodegenerative diseases. ZeNEUROID's experimental and analytical services include functional neural activity analysis, drug screening, and toxicity assays, providing comprehensive data to improve drug development.

iPSC-derived 3D and 4D neurosphere network models that replicate brain behavior and patient-specific traits

Models available using human iPSC-derived cells and mouse primary cell cultures

Functional neural activity analysis to uncover underlying mechanisms of neural processes

High-throughput drug screening service to evaluate potential therapies for brain diseases

Custom assays to assess disease-specific phenotypes and provide relevant readouts

High-throughput toxicity assays to assess drug safety and efficacy

Comprehensive toxicological profiles to refine drug discovery strategies

The primary customers are pharmaceutical companies, biotech firms, and academic research institutions involved in preclinical drug discovery and development for brain disorders such as epilepsy, schizophrenia, and Parkinson's disease.